78 related articles for article (PubMed ID: 8750280)
21. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Novitzky N; Thomas V; Hale G; Waldmann H
Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
[TBL] [Abstract][Full Text] [Related]
22. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
Knechtle SJ
Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
24. Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation.
Bunjes D; Theobald M; Wiesneth M; Schrezenmeier H; Hoffmann T; Hertenstein B; Arnold R; Heimpel H
Bone Marrow Transplant; 1993 Sep; 12(3):209-15. PubMed ID: 8241978
[TBL] [Abstract][Full Text] [Related]
25. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
26. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
[TBL] [Abstract][Full Text] [Related]
27. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
28. Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults.
Maraninchi D; Mawas C; Stoppa AM; Gaspard MH; Marit G; Van Ekthoven A; Reiffers J; Olive D; Hirn M; Delaage M
Bone Marrow Transplant; 1989 Mar; 4(2):147-50. PubMed ID: 2650783
[TBL] [Abstract][Full Text] [Related]
29. The impact of Campath 1H induction in adult liver allotransplantation.
Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
[TBL] [Abstract][Full Text] [Related]
30. Hemolytic uremic syndrome following Campath-1H induction.
Bonatti H; Brandacher G; Boesmueller C; Cont M; Hengster P; Rosenkranz AR; Krugmann J; Margreiter R
Transpl Int; 2007 Apr; 20(4):386-9. PubMed ID: 17326780
[TBL] [Abstract][Full Text] [Related]
31. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
32. Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.
Dyer MJ; Hale G; Marcus R; Waldmann H
Leuk Lymphoma; 1990; 2(3-4):179-93. PubMed ID: 27456733
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
34. Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission.
Afify Z; Hunt L; Green A; Guttridge M; Cornish J; Oakhill A
Bone Marrow Transplant; 2005 Jun; 35(11):1041-7. PubMed ID: 15806120
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
36. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
Chapuis B; Helg C; Maurice P; Wyss M; Pipard G; Irlé C; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1521-2. PubMed ID: 3909387
[TBL] [Abstract][Full Text] [Related]
37. Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation.
Deutsch VR; Nagler A; Slavin S; Condiotti R; Levine RF; Eldor A
Exp Hematol; 1993 Oct; 21(11):1427-35. PubMed ID: 8405223
[TBL] [Abstract][Full Text] [Related]
38. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
39. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning.
Chakrabarti S; Osman H; Collingham K; Milligan DW
Bone Marrow Transplant; 2003 Mar; 31(5):379-86. PubMed ID: 12634729
[TBL] [Abstract][Full Text] [Related]
40. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Osborne WL; Lennard AL
Haematologica; 2005 Jan; 90(1):ECR05. PubMed ID: 15653459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
